Arvinas Inc., a New Haven-based biotechnology company, announced this week that its drug candidate for treating prostate cancer continues to show an impact in fighting tumors.
The clinical stage company has been focused on creating a new class of drugs based on targeted protein degradation. It aims to harness the body’s natural protein disposal system to remove disease-causing proteins.
Its investigational drug candidate ARV-110, or bavdegalutamide, targets the androgen receptor, a factor in prostate cancer.
Arvinas indicated this week that it has completed Phase 1 and interim Phase 2 data for ARV-110.
“These data continue to provide evidence of anti-tumor activity and clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC),” the company said, in a press release.
ARV-110 showed evidence of tumor regression and reduction of prostate-specific antigen (PSA) levels, according to Arvinas.
The data was presented Feb. 17 at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.
John Houston, Arvinas’ president and CEO, said the results reinforce the company’s belief that bavdegalutamide “has the potential to provide meaningful clinical benefits to a patient population for which few options exist after progression of their mCRPC.”
“Overall, these data give us confidence that there is a clear path forward to accelerating the potential development of this novel treatment as a precision medicine option for patients,” Houston said, in an announcement.
Bavdegalutamide is given orally. Arvinas indicated it plans to initiate discussions with the U.S. Food and Drug Administration about the potential for an accelerated approval pathway for the treatment in a molecularly defined mCRPC population.
Arvinas plans to begin a pivotal trial by the end of the year, with future studies to explore the potential of the treatment for patients with earlier stages of disease.
Dr. Ron Peck, chief medical officer at Arvinas, said, “As an oncologist, I’m particularly excited by a precision medicine approach with the potential to identify patients who are most likely to respond to bavdegalutamide.”
Contact Michelle Tuccitto Sullo at msullo@newhavenbiz.com.
